^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PB101

    i
    Other names: PB101
    Associations

    News

    Trials
    Company:
    Panolos Biosci
    Drug class:
    VEGF-A inhibitor, Angiogenesis inhibitor, PIGF inhibitor, VEGF-B inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov)
    P1, N=30, Recruiting, Panolos Bioscience
    Trial completion date • Trial primary completion date • Immunomodulating • Metastases
    |
    FLT1 (Fms-related tyrosine kinase 1)
    |
    PB101
    1year
    Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov)
    P1, N=30, Recruiting, Panolos Bioscience | Not yet recruiting --> Recruiting
    Enrollment open • Immunomodulating • Metastases
    |
    PB101
    1year
    Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Panolos Bioscience
    New P1 trial • Immunomodulating • Metastases
    |
    PB101
    over2years
    PB101 simultaneously targets tumor angiogenesis and immunity and enhances the efficacy of PD-L1 immune checkpoint blockade (AACR 2022)
    PB101 elicited strong anti-tumor immunity more effectively than other anti-angiogenic agents. PB101 can strengthen the immunotherapeutic efficacy of PD-L1 inhibitor by establishing a potent and durable immune memory. The combination of PB101 and PD-LI needs to be further validated in clinical trials.
    Clinical • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • VEGFB (Vascular Endothelial Growth Factor B)
    |
    PB101